FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340896985> ?p ?o ?g. }

• W2340896985 endingPage "2520" @default.
• W2340896985 startingPage "2507" @default.
• W2340896985 abstract "Background Substantial concerns have been raised about the neuropsychiatric safety of the smoking cessation medications varenicline and bupropion. Their efficacy relative to nicotine patch largely relies on indirect comparisons, and there is limited information on safety and efficacy in smokers with psychiatric disorders. We compared the relative neuropsychiatric safety risk and efficacy of varenicline and bupropion with nicotine patch and placebo in smokers with and without psychiatric disorders. Methods We did a randomised, double-blind, triple-dummy, placebo-controlled and active-controlled (nicotine patch; 21 mg per day with taper) trial of varenicline (1 mg twice a day) and bupropion (150 mg twice a day) for 12 weeks with 12-week non-treatment follow-up done at 140 centres (clinical trial centres, academic centres, and outpatient clinics) in 16 countries between Nov 30, 2011, and Jan 13, 2015. Participants were motivated-to-quit smokers with and without psychiatric disorders who received brief cessation counselling at each visit. Randomisation was computer generated (1:1:1:1 ratio). Participants, investigators, and research personnel were masked to treatment assignments. The primary endpoint was the incidence of a composite measure of moderate and severe neuropsychiatric adverse events. The main efficacy endpoint was biochemically confirmed continuous abstinence for weeks 9–12. All participants randomly assigned were included in the efficacy analysis and those who received treatment were included in the safety analysis. The trial is registered at ClinicalTrials.gov (number NCT01456936) and is now closed. Findings 8144 participants were randomly assigned, 4116 to the psychiatric cohort (4074 included in the safety analysis) and 4028 to the non-psychiatric cohort (3984 included in the safety analysis). In the non-psychiatric cohort, 13 (1·3%) of 990 participants reported moderate and severe neuropsychiatric adverse events in the varenicline group, 22 (2·2%) of 989 in the bupropion group, 25 (2·5%) of 1006 in the nicotine patch group, and 24 (2·4%) of 999 in the placebo group. The varenicline–placebo and bupropion–placebo risk differences (RDs) for moderate and severe neuropsychiatric adverse events were −1·28 (95% CI −2·40 to −0·15) and −0·08 (−1·37 to 1·21), respectively; the RDs for comparisons with nicotine patch were −1·07 (−2·21 to 0·08) and 0·13 (−1·19 to 1·45), respectively. In the psychiatric cohort, moderate and severe neuropsychiatric adverse events were reported in 67 (6·5%) of 1026 participants in the varenicline group, 68 (6·7%) of 1017 in the bupropion group, 53 (5·2%) of 1016 in the nicotine patch group, and 50 (4·9%) of 1015 in the placebo group. The varenicline–placebo and bupropion–placebo RDs were 1·59 (95% CI −0·42 to 3·59) and 1·78 (−0·24 to 3·81), respectively; the RDs versus nicotine patch were 1·22 (−0·81 to 3·25) and 1·42 (−0·63 to 3·46), respectively. Varenicline-treated participants achieved higher abstinence rates than those on placebo (odds ratio [OR] 3·61, 95% CI 3·07 to 4·24), nicotine patch (1·68, 1·46 to 1·93), and bupropion (1·75, 1·52 to 2·01). Those on bupropion and nicotine patch achieved higher abstinence rates than those on placebo (OR 2·07 [1·75 to 2·45] and 2·15 [1·82 to 2·54], respectively). Across cohorts, the most frequent adverse events by treatment group were nausea (varenicline, 25% [511 of 2016 participants]), insomnia (bupropion, 12% [245 of 2006 participants]), abnormal dreams (nicotine patch, 12% [251 of 2022 participants]), and headache (placebo, 10% [199 of 2014 participants]). Efficacy treatment comparison did not differ by cohort. Interpretation The study did not show a significant increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo. Varenicline was more effective than placebo, nicotine patch, and bupropion in helping smokers achieve abstinence, whereas bupropion and nicotine patch were more effective than placebo. Funding Pfizer and GlaxoSmithKline." @default.
• W2340896985 created "2016-06-24" @default.
• W2340896985 creator A5007719765 @default.
• W2340896985 creator A5009429601 @default.
• W2340896985 creator A5010255066 @default.
• W2340896985 creator A5014230663 @default.
• W2340896985 creator A5018616843 @default.
• W2340896985 creator A5023634383 @default.
• W2340896985 creator A5048294207 @default.
• W2340896985 creator A5077623642 @default.
• W2340896985 creator A5083971769 @default.
• W2340896985 creator A5087610563 @default.
• W2340896985 date "2016-06-01" @default.
• W2340896985 modified "2023-10-16" @default.
• W2340896985 title "Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial" @default.
• W2340896985 cites W1557379673 @default.
• W2340896985 cites W1859891561 @default.
• W2340896985 cites W1993729509 @default.
• W2340896985 cites W1998258026 @default.
• W2340896985 cites W2002357983 @default.
• W2340896985 cites W2008817040 @default.
• W2340896985 cites W2028931450 @default.
• W2340896985 cites W2055445378 @default.
• W2340896985 cites W2059715562 @default.
• W2340896985 cites W2101931786 @default.
• W2340896985 cites W2114367427 @default.
• W2340896985 cites W2124679681 @default.
• W2340896985 cites W2134705835 @default.
• W2340896985 cites W2139385647 @default.
• W2340896985 cites W2141348739 @default.
• W2340896985 cites W2148083007 @default.
• W2340896985 cites W2166281097 @default.
• W2340896985 cites W2271005668 @default.
• W2340896985 cites W2417827962 @default.
• W2340896985 cites W4210565407 @default.
• W2340896985 doi "https://doi.org/10.1016/s0140-6736(16)30272-0" @default.
• W2340896985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27116918" @default.
• W2340896985 hasPublicationYear "2016" @default.
• W2340896985 type Work @default.
• W2340896985 sameAs 2340896985 @default.
• W2340896985 citedByCount "864" @default.
• W2340896985 countsByYear W23408969852016 @default.
• W2340896985 countsByYear W23408969852017 @default.
• W2340896985 countsByYear W23408969852018 @default.
• W2340896985 countsByYear W23408969852019 @default.
• W2340896985 countsByYear W23408969852020 @default.
• W2340896985 countsByYear W23408969852021 @default.
• W2340896985 countsByYear W23408969852022 @default.
• W2340896985 countsByYear W23408969852023 @default.
• W2340896985 crossrefType "journal-article" @default.
• W2340896985 hasAuthorship W2340896985A5007719765 @default.
• W2340896985 hasAuthorship W2340896985A5009429601 @default.
• W2340896985 hasAuthorship W2340896985A5010255066 @default.
• W2340896985 hasAuthorship W2340896985A5014230663 @default.
• W2340896985 hasAuthorship W2340896985A5018616843 @default.
• W2340896985 hasAuthorship W2340896985A5023634383 @default.
• W2340896985 hasAuthorship W2340896985A5048294207 @default.
• W2340896985 hasAuthorship W2340896985A5077623642 @default.
• W2340896985 hasAuthorship W2340896985A5083971769 @default.
• W2340896985 hasAuthorship W2340896985A5087610563 @default.
• W2340896985 hasBestOaLocation W23408969852 @default.
• W2340896985 hasConcept C118552586 @default.
• W2340896985 hasConcept C126322002 @default.
• W2340896985 hasConcept C142724271 @default.
• W2340896985 hasConcept C168563851 @default.
• W2340896985 hasConcept C197934379 @default.
• W2340896985 hasConcept C203092338 @default.
• W2340896985 hasConcept C204787440 @default.
• W2340896985 hasConcept C27081682 @default.
• W2340896985 hasConcept C2776087441 @default.
• W2340896985 hasConcept C2777053506 @default.
• W2340896985 hasConcept C2777843972 @default.
• W2340896985 hasConcept C2779177420 @default.
• W2340896985 hasConcept C2779547902 @default.
• W2340896985 hasConcept C2779908668 @default.
• W2340896985 hasConcept C2780687700 @default.
• W2340896985 hasConcept C535046627 @default.
• W2340896985 hasConcept C71924100 @default.
• W2340896985 hasConceptScore W2340896985C118552586 @default.
• W2340896985 hasConceptScore W2340896985C126322002 @default.
• W2340896985 hasConceptScore W2340896985C142724271 @default.
• W2340896985 hasConceptScore W2340896985C168563851 @default.
• W2340896985 hasConceptScore W2340896985C197934379 @default.
• W2340896985 hasConceptScore W2340896985C203092338 @default.
• W2340896985 hasConceptScore W2340896985C204787440 @default.
• W2340896985 hasConceptScore W2340896985C27081682 @default.
• W2340896985 hasConceptScore W2340896985C2776087441 @default.
• W2340896985 hasConceptScore W2340896985C2777053506 @default.
• W2340896985 hasConceptScore W2340896985C2777843972 @default.
• W2340896985 hasConceptScore W2340896985C2779177420 @default.
• W2340896985 hasConceptScore W2340896985C2779547902 @default.
• W2340896985 hasConceptScore W2340896985C2779908668 @default.
• W2340896985 hasConceptScore W2340896985C2780687700 @default.
• W2340896985 hasConceptScore W2340896985C535046627 @default.
• W2340896985 hasConceptScore W2340896985C71924100 @default.
• W2340896985 hasIssue "10037" @default.
• W2340896985 hasLocation W23408969851 @default.
• W2340896985 hasLocation W23408969852 @default.

• next